Oxford University Press

SHERPA: Yellow

People

  1. Mellinghoff
    Mellinghoff
  2. Young
    Young
  3. Bale
    Bale
  4. Pentsova
    Pentsova
  5. De Angelis
    De Angelis
  6. Kaley
    Kaley
  7. Karajannis
    Karajannis
  8. Arcila
    Arcila
  9. Grommes
    Grommes
  10. Farouk Sait
    Farouk Sait

Groups

  1. GSK Faculty (93)
  2. Human Oncology and Pathogenesis Program (93)
  3. Tow Center for Developmental Oncology (TCDO) (93)
  4. Radiology, Department of (32)
  5. Neuroradiology Service (30)
  6. Department of Pathology and Laboratory Medicine (27)
  7. Sloan Kettering Institute Postdocs (17)
  8. Graduate Medical Education (14)
  9. Neuro-Oncology Service (14)
  10. Pediatrics, Department of (14)
Search Within
  1. "Ingo Mellinghoff"
Formats
  1. Meeting Abstract (77)
  2. Journal Article (12)
  3. Review (3)
  4. Guidelines (1)
Groups
  1. GSK Faculty (93)
  2. Human Oncology and Pathogenesis Program (93)
  3. Tow Center for Developmental Oncology (TCDO) (93)
  4. Radiology, Department of (32)
  5. Neuroradiology Service (30)
  6. Department of Pathology and Laboratory Medicine (27)

More Groups

People
  1. Ingo Mellinghoff (93)
  2. Robert Young (23)
  3. Alexandra Miller (22)
  4. Tejus Bale (21)
  5. Elena Pentsova (19)
  6. Thomas Kaley (19)

More People

Years
  1. 2024 (18)
  2. 2023 (19)
  3. 2022 (11)
  4. 2021 (4)
  5. 2020 (6)
  6. 2019 (6)

More Years

Publications
  1. Neuro-Oncology (84)
  2. Journal of Neuropathology and Experimental Neurology (5)
  3. Annals of Oncology (4)

Results (93)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Weller, M.; Berry, D. A.; Blondin, N.; Buxton, M.; Colman, H.; de Groot, J. F.; de la Fuente, M.; Ducray, F.; Ellingson, B.; Gordon, G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of paxalisib in GBM AGILE phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Mellinghoff, I. K.; Cloughesy, T.; Alexander, B.; Berry, D. A.; Buxton, M.; Cavenee, W.; Colman, H.; de Groot, J.; Ellingson, B. M.; Gordon, G. B.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results
    Meeting Abstract

    Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress
    Meeting Abstract

    Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Lassman, A.; Alexander, B.; Berry, D.; Berry, N.; Buxton, M.; Colman, H.; Gan, H.; de Groot, J.; de la Fuente, M.; Drappatz, J.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • IDH-mutant glioma patients treated with vorasidenib: Ongoing data from the vorasidenib expanded access program
    Meeting Abstract

    Cloughesy, T.; Peters, K.; Colman, H.; Taylor, J.; Mellinghoff, I.; Shih, H.; Chacar, C.; Dewey, J.; Wen, P.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, randomized, perioperative trial of vorasidenib and ivosidenib in IDH1-mutant diffuse glioma: Updated results
    Meeting Abstract

    Mellinghoff, I.; Wen, P.; Taylor, J.; Taylor, E.; Arrillaga-Romany, I.; Ellingson, B.; Mahboub-Johnson, P.; Baron, E.; Hassan, I.; Steelman, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Prospective germline sequencing of patients with gliomas, glioneuronal or neuronal tumors
    Meeting Abstract

    Lin, A.; Nandakumar, S.; Mehine, M.; Kemel, Y.; Mandelker, D.; Karajannis, M.; Sait, S. F.; Gavrilovic, I.; Pentsova, E.; Schaff, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high-grade glioma
    Meeting Abstract

    Miller, A. M.; Nandakumar, S.; Holle, B. M.; Kreitzer, C.; Song, T.; Tartaro, M.; Hertz, C. A. J.; Rafailov, J.; Campos, C.; Brannon, A. R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid in patients with central nervous system tumors
    Meeting Abstract

    Hickman, R.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gerwitz, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save